Engineered immune cells take on recurrent brain tumors in early trial
NCT ID NCT04003649
First seen May 15, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This early-phase study tests a new treatment for glioblastoma, a serious brain cancer that has returned or not responded to standard therapy. The approach uses specially engineered immune cells (CAR T cells) designed to target and attack the tumor, combined with drugs that boost the immune system. The main goals are to check safety and see if the treatment is feasible for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.